Discovery, Characterization and Manufacture of Peptide Radiopharmaceuticals
A new wave of drugs that achieve the targeted delivery of radioisotopes are rapidly gaining momentum and attracting significant excitement. As the discovery and development pipeline widens, and new drug approvals increase, the field is expanding and becoming more diverse in the strategies employed to deliver the cell-killing radioisotopes.
One area that is showing considerable promise is the incorporation of an isotope-chelating moiety into a peptide ligand for a cell surface receptor on the cancer cells of interest. In this webinar we will discuss strategies for the discovery and optimisation of new peptide ligands for such targets, as well as their synthesis, investigation of efficacy, metabolism and distribution, and ultimately their manufacture.
Key Learning Objectives:
- Understand the latest developments in peptide radiopharmaceuticals
- Learn how new peptide leads can be identified for this modality
- See how the latest imaging technologies can help identify and characterize new diagnostic and therapeutic molecules
Who Should Attend:
- Academic and industry scientists involved in radiopharmaceutical discovery, optimization, characterization and development. All levels from laboratory scientists to business leaders in this modality area.
Brought to you by:
Speakers:
Associate Director,
WuXi AppTec
Assistant Director, Molecular Imaging Center,
WuXi AppTec
Executive Director, Head of Hits Europe,
WuXi AppTec
VP, Discovery Services,
WuXi AppTec
Contributing Editor,
C&EN Media Group
Event has ended
You can no longer attend this event.
Start:
Tue, Apr 16, 2024 11:00 AM EDT
End:
Tue, Apr 16, 2024 12:00 PM EDT
<a href='https://connect.discoveracs.org/CENWebinar_WuXiAppTec_4_16_24?partnerref=WebinarsHub'>Register</a>
